Antares Pharma, Inc. (AMEX:AIS) announced that Paul K. Wotton, Ph.D., has joined Antares Pharma as President and Chief Operating Officer. Dr. Wotton has over 20 years experience in the pharmaceutical industry with both large and specialty pharma companies.
Previously, Dr. Wotton served as CEO of Topigen Pharmaceuticals Inc., a biotechnology company in Montreal that focused on the development of novel therapeutics for the treatment of respiratory diseases. Prior to joining Topigen, Dr. Wotton served as Head of Global Business Development at SkyePharma PLC., and also held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr. Wotton received his Ph.D. in pharmaceutical science from the University of Nottingham. He is a member of the Board of Directors of Antares Pharma and the Genaera Corporation. Dr. Wotton is also past Chairman of the Emerging Companies Advisory Board of BIOTECanada.
“I am excited at the prospect of joining the Antares management team at this important time in the company’s growth. Antares has FDA approved technology platforms, substantial product opportunities and a growing revenue base. I look forward to contributing to its continued growth and future success,“ said Dr. Wotton.
“We are pleased to have Dr. Wotton, a seasoned executive, join Antares; he brings a wealth of business and product development experience to our executive management team,” commented Jack E. Stover, Chief Executive Officer and recently appointed Vice Chairman of the Board.
About Antares Pharma
Antares Pharma is a specialized pharma product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has three validated systems: the ATDTM Advanced Transdermal Gel Delivery system, subcutaneous injection technology platforms including VibexTM disposable pressure assisted auto injectors, ValeoTM/Vision® reusable needle-free injectors and disposable multi-use pen injectors; and Easy TecTM oral disintegrating tablets (ODT). Two of the systems have generated FDA approved products. Antares Pharma leverages its multiple drug delivery systems to add value to existing drugs and to create new products. The Company’s products are engineered to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.
Contacts:
Stephanie M. Baldwin
Senior Manager,
Investor Relations
609-359-3032
sbaldwin@antarespharma.com
